Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemopatrilat SCHEMBL13575789 | 1.00 | ACE (1.00) | ACEMME | |
| Gemopatrilat SCHEMBL5213866 | 1.00 | ACE (1.00) | ACEMME | |
| SCHEMBL12768553 | 0.91 | ACE (0.83) | ACEMME | |
| SCHEMBL8837701 | 0.89 | ACE (0.80) | ACEMME | |
| SCHEMBL8428348 | 0.89 | ACE (0.80) | ACEMME | |
| SCHEMBL8432189 | 0.89 | ACE (0.80) | ACEMME | |
| SCHEMBL8837724 | 0.89 | ACE (0.80) | ACEMME | |
| SCHEMBL7540477 | 0.85 | ACE (0.73) | ACEMME | |
| SCHEMBL7540483 | 0.85 | ACE (0.73) | ACEMME | |
| SCHEMBL7664525 | 0.82 | ACE (0.69) | ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569689-B2 | Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-04 | — | — | US | claimed |
| EP-1531810-A4 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1401433-A4 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | claimed |
| EP-1531810-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-05-25 | — | — | EP | claimed |
| EP-1442028-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-08-04 | — | — | EP | claimed |
| EP-1401433-A2 | CONFORMATIONALLY CONSTRAINED ANALOGS USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | Bristol-Myers Squibb Company (US) | 2004-03-31 | — | — | EP | claimed |
| WO-2004004655-A2 | SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | claimed |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | ROBL JEFFREY A (US) | 2003-10-23 | — | — | US | claimed |
| WO-2003040114-A1 | SUBSTITUTED ACID DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | claimed |
| US-6548529-B1 | AP2 (adipocyte fatty binding protein); biphenyl-substituted pyrazoles of given formula; treating diabetes and related diseases; mixtures with other antidiabetic agents such as metformin, glyburide, troglitazone and/or insulin | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-15 | — | — | US | claimed |
| US-20020086995-A1 | Recrystallization processes | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | claimed |
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | KRONENTHAL DAVID R (US) | 2002-07-04 | — | — | US | claimed |
| EP-1181014-A4 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2002-06-05 | — | — | EP | claimed |
| EP-1181014-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-27 | — | — | EP | claimed |
| US-20020004500-A1 | Vasopeptidase Inhibitors to treat isolated systolic hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-10 | — | — | US | claimed |
| WO-2001074348-A2 | VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION | BRISTOL-MYERS SQUIBB CO. (US) | 2001-10-11 | — | — | WO | claimed |
| EP-1051419-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-15 | — | — | EP | claimed |
| US-6140319-A | ADMINISTERING AN VASOPEPTIDASE INHIBITOR FOR TREATING AND/OR RELIEVING THE SYMPTOMS OF ANGINA PECTORIS | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-31 | — | — | US | claimed |
| WO-2000059506-A1 | HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB CO. (US) | 2000-10-12 | — | — | WO | claimed |
| WO-1999035145-A1 | DEPROTECTION AND RECRYSTALLIZATION PROCESSES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-07-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004500-A1 | Vasopeptidase Inhibitors to treat isolated systolic hypertension | PREP, VASP, ANPEP | ACE 6/4885MME 21/4885 |
| US-20020086994-A1 | Acylmercaptoalkanoylamino lactam esters or acids are converted to the corresponding mercaptoalkanoylamino lactam ester or acid under basic conditions using an agent that minimizes amount of disulfides | MPST, PTMS, TST | ACE 315/4885MME 493/4885 |
| US-20030199563-A1 | Heterocyclic containing biphenyl aP2 inhibitors and method | AP2B1, AP2A2, AP2A1 | ACE 1554/4885MME 3530/4885 |
| US-20020086995-A1 | Recrystallization processes | MPST, TST, SLC39A11 | ACE 1296/4885MME 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.